In recent years, proton pump inhibitors have come under scrutiny for a rising number of associated adverse effects in the general population, including increased susceptibility to enteric infection, 2 chronic kidney disease, 3 dementia 4 and stroke. 5 Proton pump inhibitors have also garnered increasing attention for their potentially deleterious effects in patients with cirrhosis, for whom proton pump inhibitors are frequently prescribed even in the absence of an acid-related disease. 6 Specifically, a number of recent studies have uncovered associations between proton pump inhibitors and increased rates of complications in cirrhotics, including spontaneous bacterial peritonitis, 7 hepatic encephalopathy, 8 infections 9 and overall mortality, 10 although not all studies have supported such associations. 11, 12 It is postulated that proton pump inhibitors mediate these effects through several mechanisms, including small intestinal bacterial overgrowth, increased intestinal permeability and bacterial translocation.
Two recent studies have shown that administration of proton pump inhibitors leads to significant alterations in the gut microbiota composition, including decreased bacterial diversity and increased numbers of potentially pathogenic bacteria. 13, 14 Interestingly, decreased gut biodiversity, increased burden of pathogenic bacteria and distal translocation of upper gastrointestinal flora have all been characterised as features of the cirrhotic gut microbiome. [15] [16] [17] Whether gut dysbiosis contributes to progression of chronic liver disease remains an area of open and active investigation.
To date, most studies evaluating the link between proton pump inhibitor exposure and liver disease have focused on cirrhotics. In contrast, we sought to investigate the impact of proton pump inhibitors in a noncirrhotic cohort on the development of incident cirrhosis, hepatic decompensation and hepatocellular carcinoma by utilising a large, well-established national database of HCV-infected US veterans.
2 | ME TH ODS
| Definitions
Baseline was defined as the date of HCV treatment initiation. Treatment completion was defined according to the US Food and drug administration approved labels for each drug regimen. Cirrhosis was defined as a FIB-4 score of > 3.5 based on previously published work 18 and was calculated as follows:
FIB-4 ¼ðage ½years Â AST½IU/LÞ=ðplatelet count ½platelets Â 10 9 =L Â ALT 1=2 ½IU/LÞ Laboratory data were obtained at yearly intervals and the FIB-4
score was recalculated at each interval. An average of two values closest to the selected time point of interest was used for the calculation of FIB-4 scores. Sustained virologic response was defined as undetectable HCV RNA in all follow-up HCV RNA tests after the end of treatment, with at least 1 test more than 12 weeks after the end of initial treatment. Hepatic decompensation was defined as the development of ascites, spontaneous bacterial peritonitis or variceal haemorrhage as evidenced by 1 in-patient or ≥ 2 out-patient ICD-9-CM codes based on a validated algorithm developed in VA populations. 19 The incidence of hepatic encephalopathy and hepatorenal syndrome was not able to be assessed by this algorithm due to relatively poor test characteristics in a validation cohort. 19 Hepatocellular carcinoma was defined as the presence of at least 2 ICD-9-CM for a chronic liver disease plus 2 ICD-9-CM codes for hepatocellular carcinoma based on another validated algorithm developed in VA populations. 20 Patients were defined as having diabetes as previously described using a combination of blood glucose measurement, use of anti-diabetic agents and ICD-9 codes. 21 A history of alcohol or drug abuse/dependence was identified based on the presence of at least 1 in-patient or 2 out-patient ICD-9 diagnoses. The diagnosis of gastro-oesophageal varices was also based on the presence of at least 1 in-patient or 2 out-patient ICD-9 diagnoses. A history of peptic ulcer disease, gastro-oesophageal reflux disease and
Helicobacter pylori infection was based on at least one ICD-9 code for each of these diagnoses. received their first prescription of proton pump inhibitors after their first diagnosis of cirrhosis.
| Study population

| Exposure to acid-suppressive therapy
All patients who were prescribed proton pump inhibitors or histamine-2 receptor antagonists in any VA pharmacy during the study observation period were identified. Analysis was performed on patients who were exposed to either proton pump inhibitors or histamine-2 receptor antagonists, but not both, as described above.
Proton pump inhibitor prescriptions included omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole and rabeprazole. Histamine-2 receptor antagonist prescriptions included famotidine, ranitidine and cimetidine. Information regarding the dates of prescriptions ordered, number of days prescribed, number of pills per prescription and number of refills ordered were collected. Using this information, the cumulative defined daily dose (cDDD) of proton pump inhibitors or histamine-2 receptor antagonists was calculated for each subject as described previously. 21 Briefly, we collected the dates of prescriptions ordered, the number of days prescribed, number of pills per prescription and number of refills ordered. Using this, the defined daily dose (DDD) of acidsuppressive therapy was calculated. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults and is defined by the World Health Organization for each drug. 23 
| Outcomes
Primary outcome measures were (1) development of cirrhosis as defined by FIB-4 score ≥ 3.5, (2) development of hepatic decompensation and (3) incident hepatocellular carcinoma.
| Statistical analysis
The study cohort was divided into those who had been exposed to acid-suppressive therapy and those who had not. Baseline demographic and clinical factors were compared between the two groups using Chi-squared test or t test, as appropriate. Predictors of incident cirrhosis, hepatic decompensation and hepatocellular carcinoma were determined using Cox's proportional hazards analysis and generating hazard ratios for each of the predictor variables. In all the Cox models, the assumption of proportionality was met. Mean fibrosis scores were plotted over time by the cDDD of acid-suppressive therapy used. Kaplan-Meier curves were generated to demonstrate time to development of cirrhosis, hepatic decompensation and hepatocellular carcinoma by proton pump inhibitor and histamine-2 receptor antagonist cDDDs. SAS (version 9.4, SAS Institute Inc., Cary, NC) was used for statistical analyses. were also similar between both groups. Furthermore, baseline aminotransferase levels, platelet count and baseline FIB-4 score (1.77 vs 1.77; P = .77) were comparable in both groups. The proton pump inhibitor-exposed group had somewhat higher rates of diabetes, obesity, history of alcohol abuse/dependence and statin use. Proton pump inhibitor users were less likely to achieve sustained virologic response compared to proton pump inhibitor nonusers (51.94% vs 55.90%; P <.0001). In both groups, there was a similar number of individuals for whom sustained virologic response was unable to be determined due to lack of follow-up 
| Effect of proton pump inhibitor exposure on the development of cirrhosis
To assess the effect of proton pump inhibitor use on the risk of progression to cirrhosis, we performed a multivariate Cox regression analysis adjusting for univariate predictors of cirrhosis including body mass index, diabetes and alcohol use as well as baseline FIB-4 score.
We also adjusted for the presence of indications for proton pump inhibitor use including gastro-oesophageal reflux disease, peptic ulcer disease and H. pylori infection to minimise confounding by indication.
Proton pump inhibitor users were divided into groups based upon drug exposure: cDDD 30-180, cDDD 181-540, cDDD 541-900, cDDD >900 and an unexposed group. After adjusting for potential confounders, we found that proton pump inhibitor use was an independent risk factor for the development of cirrhosis (Table 2 ). For patients with relatively limited exposure to proton pump inhibitors, proton pump inhibitors did not significantly affect the risk of developing cirrhosis compared to non-users. However, with increasing proton pump inhibitor exposure, there is a gradual, dose-dependent increase in the risk of cirrhosis. For patients with cDDDs > 900, the adjusted hazard ratio of cirrhosis development was 1.32 (95% CI:
1.17, 1.49; P < .001), respectively, compared to non-users (Table 2) .
Furthermore, the cumulative probability of cirrhosis over 10 years of follow-up by Kaplan-Meier analysis was significantly higher in patients who received proton pump inhibitor therapy (P < .001 using the log-rank test; Figure 2 ) and that the risk of cirrhosis increased in a dose-dependent manner (P = .003 using the log-rank test; consistent with previous studies.
18,21
We next sought to address numerous sources of potential confounding in our study. Given that failure to achieve sustained virologic response is one of the most powerful predictors of cirrhosis development; we first assessed contributions of potential confounding by sustained virologic response status. To do so, we performed
Kaplan-Meier analysis of cirrhosis-free survival among proton pump inhibitor users and non-users stratified by sustained virologic response status. In this analysis, we found that among the subgroup of individuals who achieved sustained virologic response, exposure to proton pump inhibitors remained significantly associated with accelerated development of cirrhosis (P = .03; Figure 4 ). This association was also significant among proton pump inhibitor non-users
Alcohol use is another independent risk factor for the development of cirrhosis. As such, we conducted additional sensitivity analyses excluding those with a diagnosis of alcohol abuse/dependence at baseline or during follow-up. In this cohort, proton pump inhibitor exposure remained significantly associated with an increased risk of cirrhosis with an adjusted hazard ratio of 1.22 for cDDD > 900 (95% CI: 1.06, 1.4; P = .01; Table S1 ).
We also wanted to ensure that bias was not introduced into this study as a result of minimal exposure to proton pump inhibitors prior to a diagnosis of cirrhosis, as we hypothesise that low levels of exposure to a relatively nonhepatotoxic drug such as proton pump inhibitors are unlikely to significantly influence the course of a chronically evolving disease like cirrhosis. As such, we determined the level of drug exposure among proton pump inhibitor users prior to achieving a diagnosis of cirrhosis. We found that among proton pump inhibitor users who developed incident cirrhosis (n = 902), 67.3% and 31.9% were exposed to > 180 cDDDs and > 900 cDDDs prior to a diagnosis of cirrhosis respectively. The mean pre-cirrhotic drug exposure among proton pump inhibitor users was 874 cDDDs.
Overall, among proton pump inhibitor users, 58.7% of proton pump inhibitors were prescribed prior to a diagnosis of cirrhosis. These | 249
T A B L E 1 Baseline clinical and laboratory characteristics of HCV-infected patients without baseline cirrhosis with and without proton pump inhibitor exposure findings show that a spurious association was unlikely to be introduced into our study because of trivial pre-cirrhotic exposure to proton pump inhibitors.
Finally, we sought to assess whether the effect that we observed on cirrhosis development was specific to proton pump inhibitors or was generalisable to acid-suppressive therapy in general. As such,
we performed a parallel analysis using identical methods on individuals with exposure to histamine-2 receptor antagonists. The overall demographic and clinical characteristics of the cohort of histamine-2 receptor antagonist users (n = 886) vs non-users (n = 10 640) are described in Table S2 . We found that histamine-2 receptor antagonist use was not significantly associated with an increased likelihood of developing cirrhosis (adjusted hazard ratio for cDDD > 900: 1.07; 95% CI: 0.73, 1.58; P = .73); Table S3 ).
| Proton pump inhibitor effect on the development of hepatic decompensation
We also evaluated the association of proton pump inhibitor use in (Table 3) . Notably, histamine-2 receptor antagonist users did not exhibit the same increase in risk of hepatic decompensation regardless of dose (Table S4 ). Over 10 years of follow-up, we also found that proton pump inhibitor use with an accelerated risk of developing a decompensation event (log-rank test; P < .001; Figure 5 ) and the risk of hepatic decompensation increased in a dose-dependent manner (log-rank test; P = .002; Figure 6 ).
Proton pump inhibitor use was also associated with a significantly increased risk of developing hepatocellular carcinoma with a confounder-adjusted hazard ratio for cDDD > 900 of 2.01 (95% CI:
1.5, 2.7; P < .001) ( Table 4 ). In contrast, histamine-2 receptor antagonist use was not associated with an increased risk of hepatocellular carcinoma (Table S5 ). Other identified risk factors for hepatocellular carcinoma include increased age while statin use and achievement of sustained virologic response were associated with a decreased risk of hepatocellular carcinoma.
| DISCUSSION
In this large, national, well-defined cohort of HCV-infected veterans without a prior diagnosis of cirrhosis, we found that proton pump inhibitor use is independently associated with an accelerated progression to cirrhosis independent of having attained sustained Changes include a decrease in the diversity of the gut microbiome, a decrease in the bacterial families Lachnospiraceae and Ruminococcaceae, an increase in oral and upper GI tract bacteria including Streptococcaceae and Micrococcaceae and an increase in the bacterial class Gammaproteobacteria, which include Enterobacteriaceae.
These changes are likely due to reduced acidity of the upper GI tract due to proton pump inhibitor use, allowing for the distal colonisation of microflora normally confined to the upper GI tract. Several recent studies have also investigated the composition of the gut microbiome in cirrhotics. Intriguingly, these showed a marked similarity to that of the proton pump inhibitor-treated microbiome, including a F I G U R E 3 Kaplan-Meier curve for probability of cirrhosis-free survival in patients with chronic hepatitis C stratified by exposure level to proton pump inhibitors. Cirrhosis was defined as FIB-4 score > 3.5. P values calculated by log-rank test. PPI = proton pump inhibitor; cDDD = cumulative defined daily dose decrease in bacterial diversity, a decrease in "healthy" bacterial populations including Lachnospiraceae and an increase in pathogenic bacteria including Enterobacteriaceae and Streptococcaceae. [15] [16] [17] Moreover, increasing severity of liver disease was associated with more significant changes in the gut microbiome.
Dysbiosis is thought to contribute to the pathophysiology of hepatic fibrosis by leading to increased translocation of enteric bacteria, resulting in higher levels of bacterial products including endotoxin in the portal circulation, which subsequently incite an inflammatory reaction as they reach the liver leading to the development of fibrosis. This leads to the activation of Toll-like receptors, which recognise pathogen-associated molecular patterns. 25 Activation of Toll-like receptors on a variety of cell types, including Kupffer cells and hepatic stellate cells, subsequently leads to the production of pro-inflammatory cytokines (ie TNF-a, IL-6), which has been linked, with hepatic injury and to acceleration of hepatic fibrogenesis 26 as well as hepatocellular carcinogenesis. 27 Interestingly, variants of the Toll-like receptor 4 gene (TLR4) have been reported that modulate the risk for liver fibrosis in Caucasian patients with chronic HCV infection. 28, 29 Translocation of enteric bacteria is thought to be driven by several factors, including bacterial overgrowth and increased intestinal permeability. The connection between proton pump inhibitors and small intestinal bacterial overgrowth has recently been evaluated in several studies and is thought to be due to the abrogation of the acidic host defence in the stomach. 30, 31 Recently, proton pump inhibitor-induced bacterial overgrowth has been implicated in the pathogenesis of some disease states including nonsteroidal anti-inflammatory drug-induced enteropathy. 32 In one study, duodenal aspirates retrieved from patients with small intestinal bacterial overgrowth who had been treated with proton pump inhibitors were found to predominantly have overgrowth of Streptococcus, Enterococcus and members of the Enterobacteriaceae family, consistent with what is observed in the distal gut microbiome of healthy patients treated with proton pump inhibitors. 33 Although proton pump inhibitor use has not been directly linked with increased intestinal permeability to date, dysbiosis itself has been increasingly linked with chronic intestinal inflammation which leads impaired gut barrier function and bacterial translocation. 34 For example, repeated administration of the oral microbe Porphyromonas gingivalis leads to altered distal gut microbiota, downregulation of genes involved in maintaining intestinal wall integrity and higher amounts of bacterial DNA in the liver as well as serum endotoxin levels. 35 Overall, those with chronic liver disease and particularly those with cirrhosis may be particularly predisposed to the potentially harmful effects of proton pump inhibitors as this class of medication predominantly undergoes hepatic metabolism. Interestingly, the effect was only significant in individuals exposed to proton pump inhibitors and not to those exposed to histamine-2 receptor antagonists, which has been previously observed in a study investigating the association between bacterial infections in decompensated cirrhosis and acid suppression. 36 However, we cannot exclude the possibility that at extremely high exposures of histamine-2 receptor antagonists, there holic steatohepatitis compared to wild-type mice. 38 Moreover, this was associated with overgrowth of Enterococcus species, which was sufficient by itself to cause worsened alcoholic liver injury. with baseline cirrhosis, hepatocellular carcinoma and those who were exposed to proton pump inhibitors only after being diagnosed with cirrhosis. We also adjusted for various risk factors for advanced liver disease including alcohol use and sustained virologic response status and found that our observed associations remained robust to sensitivity analyses involving both of these risk factors. Moreover, to account for the possibility that patients with a higher risk of liver disease progression to cirrhosis and subsequent adverse hepatic outcomes may reflect a population that is at high risk of being prescribed a proton pump inhibitor, we adjusted for conditions that were associated with proton pump inhibitor use including gastro- Probability without hepatic decompensation 9 10 F I G U R E 6 Kaplan-Meier curve for probability of hepatic decompensation in patients stratified by exposure levels to proton pump inhibitors. P values calculated by log-rank test. PPI = proton pump inhibitor; cDDD = cumulative defined daily dose
Limitations of this study include its nonrandomised study design, which opens the study to potential selection bias and unmeasured confounding variables. We also note that proton pump inhibitor users had slightly higher body mass index as well as mildly increased rates of diabetes and alcohol use, all of which have been associated with increased severity of liver disease. However, after multivariate Cox regression analyses to adjust for these potential confounders, proton pump inhibitor use was still found to be an independent risk factor for adverse hepatic outcomes. Indeed, while residual confounding cannot be entirely excluded in such an observational study, with a very large cohort, we could control for many observed and well-described risk factors for cirrhosis and increased disease severity in our adjusted multivariable models. As such, our findings are unlikely to be due to confounding alone. Another limitation of this study was the use of a clinical score (the FIB-4 score) as a surrogate to identify those patients with cirrhosis as opposed to liver biopsy, transient elastography or radiologic findings. However, the FIB-4 is a validated and widely used marker of liver fibrosis progression 46 and has been frequently used in epidemiological studies as a surrogate for a diagnosis of cirrhosis. 47, 48 Moreover, the use of such a large sample size may minimise the variance otherwise attributable to this index score. Another limitation of this study is its use of prescription data, which may not accurately reflect patient adherence and also does not account for any over the counter use of acid-suppressive therapy.
In conclusion, our study demonstrates a significant association between proton pump inhibitors and a higher risk of fibrosis pro- 
